机构风向标 | 康华生物(300841)2025年二季度机构持仓风向标

Core Viewpoint - Kanghua Biological (300841.SZ) reported its semi-annual results for 2025, highlighting significant institutional investment and changes in shareholding patterns among public funds and social security funds [1][2]. Group 1: Institutional Investors - As of August 26, 2025, a total of 10 institutional investors disclosed holdings in Kanghua Biological A-shares, with a combined holding of 42.33 million shares, representing 31.84% of the total share capital [1]. - The top ten institutional investors include notable entities such as Aokang Group Co., Ltd. and China Bank Co., Ltd. - Huaxia Industry Prosperity Mixed Securities Investment Fund, among others [1]. - Compared to the previous quarter, the combined holding percentage of the top ten institutional investors increased by 0.17 percentage points [1]. Group 2: Public Funds - In the current period, one public fund, Huaxia Industry Prosperity Mixed Fund, increased its holdings, with an increase percentage of 0.66% [1]. - Two new public funds disclosed their holdings this quarter, including Southern CSI 1000 ETF and Changjiang CSI 300 Index Enhanced A [1]. Group 3: Social Security Funds - For social security funds, one fund, Huaxia Fund Management Co., Ltd. - Social Security Fund 422 Combination, increased its holdings by 0.20% compared to the previous period [2]. Group 4: Foreign Investment - There were no new disclosures from foreign institutions this quarter, with Hong Kong Central Clearing Limited not reporting any changes [2].